Characterization and transplantation of induced megakaryocytes from hematopoietic stem cells for rapid platelet recovery by a two-step serum-free procedure
- PMID: 19664680
- DOI: 10.1016/j.exphem.2009.07.012
Characterization and transplantation of induced megakaryocytes from hematopoietic stem cells for rapid platelet recovery by a two-step serum-free procedure
Abstract
Objective: A complete process for mass generation of megakaryocytes from hematopoietic stem cells under serum-free conditions has great clinical potential for rapid platelet reconstruction in thrombocytopenia patients. We have previously reported on the generation of an optimized serum-free medium (serum-free hematopoietic stem cell medium) for ex vivo expansion of CD34(+) cells. Here, we further generated large amounts of functional megakaryocytes from serum-free expanded CD34(+) cells under a complete and optimal serum-free condition for complying with clinical regulations.
Materials and methods: Serum substitutes and cytokines were screened and optimized for their concentration for megakaryocyte generation by systemically methods. Serum-free induced megakaryocytes were characterized by surface antigens, gene expression, ex vivo megakaryocyte activation ability, and ability of megakaryocyte and platelet recovery in nonobese diabetic/severe combined immunodeficient mice.
Results: The optimal serum-free megakaryocyte induction medium was Iscove's modified Dulbecco's medium containing serum substitutes (i.e., human serum albumin, human insulin, and human transferrin) and a cytokine cocktail (i.e., thrombopoietin, stem cell factor, Fms-like tyrosine kinase 3 ligand, interleukin-3, interleukin-6, interleukin-9, and granulocyte-macrophage colony-stimulating factor). After induction, induced megakaryocytes expressed CD41a and CD61 surface antigens, nuclear factor erythroid-derived 2 and GATA-1 transcription factors and megakaryocyte activation ability. Importantly, transplantation of induced megakaryocytes could accelerate megakaryocyte and platelet recovery in irradiated nonobese diabetic/severe combined immunodeficient mice.
Conclusion: In conclusion, we have developed a serum-free megakaryocyte induction medium, and the combination of serum-free megakaryocyte and serum-free hematopoietic stem cell media can generate a large amount of functional megakaryocytes efficiently. Our method represents a promising source of megakaryocytes and platelets for future cell therapy.
Similar articles
-
Long-term platelet production assessed in NOD/SCID mice injected with cord blood CD34+ cells, thrombopoietin-amplified in clinical grade serum-free culture.Exp Hematol. 2008 Feb;36(2):244-52. doi: 10.1016/j.exphem.2007.09.006. Epub 2007 Nov 26. Exp Hematol. 2008. PMID: 18023520
-
Large generation of megakaryocytes from serum-free expanded human CD34+ cells.Biochem Biophys Res Commun. 2009 Jan 2;378(1):112-7. doi: 10.1016/j.bbrc.2008.11.019. Epub 2008 Nov 21. Biochem Biophys Res Commun. 2009. PMID: 19010306
-
[In vitro expansion of cord blood megakaryocyte progenitor].Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Apr;27(2):199-204. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005. PMID: 15960266 Chinese.
-
Ex vivo expansion of megakaryocytic cells.Int J Hematol. 2000 Apr;71(3):203-10. Int J Hematol. 2000. PMID: 10846824 Review.
-
Thrombopoietin: biology and clinical potentials.Int J Hematol. 1999 Dec;70(4):216-25. Int J Hematol. 1999. PMID: 10643146 Review.
Cited by
-
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23. Blood. 2014. PMID: 24859366 Free PMC article. Clinical Trial.
-
Good Manufacturing Practice-Grade of Megakaryocytes Produced by a Novel Ex Vivo Culturing Platform.Clin Transl Sci. 2020 Nov;13(6):1115-1126. doi: 10.1111/cts.12788. Epub 2020 Oct 8. Clin Transl Sci. 2020. PMID: 33030809 Free PMC article.
-
Infusion of megakaryocytic progenitor products generated from cord blood hematopoietic stem/progenitor cells: results of the phase 1 study.PLoS One. 2013;8(2):e54941. doi: 10.1371/journal.pone.0054941. Epub 2013 Feb 4. PLoS One. 2013. PMID: 23390507 Free PMC article. Clinical Trial.
-
Recent developments in ex vivo platelet production.Cytotechnology. 2016 Dec;68(6):2211-2221. doi: 10.1007/s10616-016-9963-4. Epub 2016 Mar 22. Cytotechnology. 2016. PMID: 27002966 Free PMC article. Review.
-
Three-stage ex vivo expansion of high-ploidy megakaryocytic cells: toward large-scale platelet production.Tissue Eng Part A. 2013 Apr;19(7-8):998-1014. doi: 10.1089/ten.TEA.2011.0111. Epub 2013 Jan 14. Tissue Eng Part A. 2013. PMID: 23190353 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous